Back HBV Treatment

HBV Treatment

HBV Rebounds After Stopping Entecavir, Switching to Interferon May Help

Most hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B patients relapsed after stopping treatment with the antiviral drug entecavir (Baraclude), according to a report in the May 15 online edition of Gut. A related study found that switching from entecavir to pegylated interferon increased the likelihood of HBeAg seroconversion and hepatitis B surface antigen(HBsAg) lossin HBeAg positive patients.

alt

Read more:

No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment

No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.

alt

Read more:

Antiviral Treatment for Hepatitis B Lowers Risk of Liver Cancer

Antiviral therapy for chronic hepatitis B virus (HBV) infection can reduce the risk of developing hepatocellular carcinoma (HCC), even among people with high HBV viral load, according to research described in the May 2014 edition of Clinical Gastroenterology and Hepatology.

alt

Read more:

DDW 2014: Some Hepatitis B Patients Can Stop Antiviral Treatment without Relapse

Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.

alt

Read more: